Mineralys Therapeutics, Inc.
Price
Overview
Mineralys Therapeutics, Inc. (MLYS) is a pioneering biopharmaceutical company currently advancing through clinical trials. Its primary focus lies in creating innovative treatments for high blood pressure and its related cardiovascular complications. The company's leading investigational drug is lorundrostat. This exclusive, orally administered compound functions as a highly targeted aldosterone synthase inhibitor, specifically being developed to address difficult-to-treat cases of uncontrolled or resistant hypertension. Established in 2019, Mineralys Therapeutics operates from its headquarters in Radnor, Pennsylvania.
History & business model
This section is waiting to be written.
InvestWiki is community-edited. Contribute a plain-English history of Mineralys Therapeutics, Inc., its business model, key products, and controversies.